## Johannes C Nossent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3752323/publications.pdf

Version: 2024-02-01

218677 118850 4,218 111 26 62 citations g-index h-index papers 118 118 118 6060 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Research, 2018, 6, 15.	11.4	947
2	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genetics, 2013, 45, 730-738.	21.4	699
3	The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatology International, 2021, 41, 863-877.	3.0	297
4	Increased mortality in ankylosing spondylitis is related to disease activity. Annals of the Rheumatic Diseases, 2011, 70, 1921-1925.	0.9	238
5	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nature Communications, 2015, 6, 7146.	12.8	220
6	Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrual. Lupus, 2007, 16, 309-317.	1.6	189
7	Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus, 2010, 19, 949-956.	1.6	134
8	Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology, 2013, 52, 2041-2047.	1.9	94
9	The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies. Journal of Rheumatology, 2021, 48, 669-676.	2.0	89
10	<i>ERAP2</i> is associated with ankylosing spondylitis in <i>HLA-B27</i> positive and <i>HLA-B27-</i> positive patients. Annals of the Rheumatic Diseases, 2015, 74, 1627-1629.	0.9	86
11	Levels of Transforming Growth Factor- $\hat{l}^2$ Are Low in Systemic Lupus Erythematosus Patients with Active Disease. Journal of Rheumatology, 2010, 37, 2039-2045.	2.0	73
12	Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology, 2014, 53, 1818-1824.	1.9	65
13	Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2017, 46, 513-519.	3.4	58
14	Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. Journal of Rheumatology, 2008, 35, 380-6.	2.0	56
15	B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. Clinical Rheumatology, 2010, 29, 1031-1035.	2.2	50
16	Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case–control study. Rheumatology, 2011, 50, 2197-2205.	1.9	49
17	Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 447-451.	3.4	46
18	Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 545-550.	0.5	40

#	Article	IF	CITATIONS
19	Work Disability in Patients with Ankylosing Spondylitis in Norway. Journal of Rheumatology, 2011, 38, 479-484.	2.0	37
20	Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA–B27. Arthritis Care and Research, 2013, 65, 448-453.	3.4	36
21	The Influence of the 1997 Updated Classification Criteria for Systemic Lupus Erythematosus: Epidemiology, Disease Presentation, and Patient Management. Journal of Rheumatology, 2009, 36, 552-559.	2.0	34
22	Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. Arthritis Research and Therapy, 2012, 14, R28.	3.5	34
23	Low Copy Number of the Fc-γ Receptor 3B Gene <i>FCGR3B</i> Is a Risk Factor for Primary Sjögren's Syndrome. Journal of Rheumatology, 2012, 39, 2142-2147.	2.0	33
24	Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Research and Therapy, 2006, 8, R162.	3.5	28
25	Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?. Clinical Rheumatology, 2013, 32, 1677-1681.	2.2	28
26	Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study. Lupus Science and Medicine, 2014, 1, e000007.	2.7	28
27	Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. International Journal of Hematology, 2013, 97, 800-803.	1.6	27
28	Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study. Scandinavian Journal of Rheumatology, 2013, 42, 311-316.	1.1	27
29	IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. European Journal of Rheumatology, 2017, 4, 29-35.	0.6	26
30	Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study. BMC Cardiovascular Disorders, 2016, 16, 256.	1.7	25
31	Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clinical Rheumatology, 2012, 31, 1263-1265.	2.2	22
32	The Risk and Consequences of Vertebral Fracture in Patients with Ankylosing Spondylitis: A Population-based Data Linkage Study. Journal of Rheumatology, 2020, 47, 1629-1636.	2.0	22
33	Tumor Necrosis Factor–α Promoter â^'308/238 Polymorphism Association with Less Severe Disease in Ankylosing Spondylitis is Unrelated to Serum TNF-α and Does Not Predict TNF Inhibitor Response. Journal of Rheumatology, 2014, 41, 1675-1682.	2.0	21
34	Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis. Rheumatology International, 2013, 33, 2687-2689.	3.0	19
35	Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades. Rheumatology and Therapy, 2020, 7, 685-702.	2.3	17
36	Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus. Cytokine, 2019, 114, 67-73.	3.2	16

#	Article	IF	CITATIONS
37	Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. Nephrology Dialysis Transplantation, 2011, 26, 620-627.	0.7	15
38	The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis. Lupus, 2018, 27, 1838-1846.	1.6	13
39	Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation. Lupus Science and Medicine, 2016, 3, e000162.	2.7	12
40	Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2018, 32, 400-405.	2.3	12
41	The accuracy of administrative health data for identifying patients with rheumatoid arthritis: a retrospective validation study using medical records in Western Australia. Rheumatology International, 2021, 41, 741-750.	3.0	12
42	Smoking associates with increased BAFF and decreased interferon- $\hat{I}^3$ levels in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000537.	2.7	12
43	Insulin-like growth factor-1 (IGF1) in systemic lupus erythematosus: relation to disease activity, organ damage and immunological findings. Lupus, 2018, 27, 963-970.	1.6	11
44	Morbidity and mortality in adult-onset IgA vasculitis: a long-term population-based cohort study. Rheumatology, 2021, 61, 291-298.	1.9	11
45	Frequency, presentation, and outcome of Takayasu arteritis in Western Australia. Modern Rheumatology, 2017, 27, 1019-1023.	1.8	10
46	Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus. Journal of Immunology Research, 2018, 2018, 1-7.	2.2	10
47	Infection Rates Before and After Diagnosis of IgA Vasculitis in Childhood: A Population-wide Study Using Non-exposed Matched Controls. Journal of Rheumatology, 2020, 47, 424-430.	2.0	10
48	The influence of ERAP1 gene variants on clinical phenotype in ankylosing spondylitis. Scandinavian Journal of Rheumatology, 2016, 45, 474-479.	1.1	9
49	Pregnancy outcomes in women with a history of immunoglobulin A vasculitis. Rheumatology, 2019, 58, 884-888.	1.9	9
50	Septic Arthritis in Children: A Longitudinal Population-Based Study in Western Australia. Rheumatology and Therapy, 2021, 8, 877-888.	2.3	9
51	Mortality Rates in Patients With Ankylosing Spondylitis With and Without Extraarticular Manifestations and Comorbidities: A Retrospective Cohort Study. Journal of Rheumatology, 2022, 49, 688-693.	2.0	9
52	Mortality and cause of death in patients with ANCA-associated vasculitis and polyarteritis nodosa in Australia—a population-based study. Rheumatology, 2022, 61, 1062-1071.	1.9	8
53	CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in Granulomatosis with polyangiitis patients. PeerJ, 2016, 4, e2487.	2.0	8
54	Total Hip Replacement in Patients with Rheumatoid Arthritis: Trends in Incidence and Complication Rates Over 35ÂYears. Rheumatology and Therapy, 2022, 9, 565-580.	2.3	8

#	Article	IF	Citations
55	Infection Risks During Longterm Rituximab Therapy Change Over Time. Journal of Rheumatology, 2013, 40, 203.1-203.	2.0	7
56	Renal histology in Indigenous Australians with lupus nephritis. International Journal of Rheumatic Diseases, 2018, 21, 194-199.	1.9	7
57	Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis. PeerJ, 2015, 3, e1051.	2.0	7
58	Susceptibility for Lupus Nephritis by Low Copy Number of the <i>FCGR3B &lt; /i&gt; Gene Is Linked to Increased Levels of Pathogenic Autoantibodies. Autoimmune Diseases, 2013, 2013, 1-6.</i>	0.6	6
59	Hospitalisation rates and characteristics for adult and childhood immunoglobulin A vasculitis in Western Australia. Internal Medicine Journal, 2019, 49, 475-481.	0.8	6
60	The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus. Journal of Clinical Medicine, 2019, 8, 857.	2.4	6
61	Cancer diagnosis and mortality in patients with ankylosing spondylitis: A Western Australian retrospective cohort study. International Journal of Rheumatic Diseases, 2021, 24, 216-222.	1.9	6
62	The temporal association between hospital admissions, biological therapy usage and direct healthÂcare costs in rheumatoid arthritis patients. Rheumatology International, 2022, 42, 2027-2037.	3.0	6
63	Thrombopoietin levels in systemic lupus erythematosus are linked to inflammatory cytokines, but unrelated to thrombocytopenia or thrombosis. Lupus, 2015, 24, 18-24.	1.6	5
64	The importance of tubuloreticular inclusions in lupus nephritis. Pathology, 2019, 51, 727-732.	0.6	5
65	Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis. Rheumatology and Therapy, 2019, 6, 369-378.	2.3	5
66	No Zinc Deficiency But a Putative Immunosuppressive Role for Labile Zn in Patients with Systemic Autoimmune Disease. Current Rheumatology Reviews, 2017, 13, 59-64.	0.8	5
67	Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study. Lupus Science and Medicine, 2021, 8, e000539.	2.7	5
68	Long-Term Risk of Comorbidity after IgA Vasculitis in Childhood: A Population-Based Cohort Study. Rheumatology and Therapy, 2020, 7, 927-935.	2.3	4
69	Disease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia. International Journal of Clinical Rheumatology, 2019, 14, .	0.3	4
70	Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE). RMD Open, 2022, 8, e002301.	3.8	4
71	IL23R gene variants in relation to IL17A levels and clinical phenotype in patients with ankylosing spondylitis. Rheumatology Advances in Practice, 2018, 2, rky006.	0.7	3
72	Validity of Self-reported Diagnosis of Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 781.1-781.	2.0	3

#	Article	IF	Citations
<b>7</b> 3	IL-1A gene variation in relation to cytokine levels and clinical characteristics in ankylosing spondylitis. European Journal of Rheumatology, 2019, 6, 64-67.	0.6	3
74	Septic arthritis due to <scp><i>Neisseria gonorrhoea</i></scp> in Western Australia. Internal Medicine Journal, 2022, 52, 1029-1034.	0.8	3
75	The Association Between TNF Inhibitor Therapy Availability and Hospital Admission Rates for Patients with Ankylosing Spondylitis. A Longitudinal Population-Based Study. Rheumatology and Therapy, 2022, 9, 127-137.	2.3	3
76	Rheumatoid factors do not predict cardiovascular disease and mortality in the general population in the Busselton Health Survey. BMC Musculoskeletal Disorders, 2017, 18, 221.	1.9	2
77	Sporadic late onset nemaline myopathy (SLONM) in an adult presenting with progressive muscle weakness. European Journal of Rheumatology, 2019, 6, 103-105.	0.6	2
78	OP0100-HPRâ€THE INFLUENCE OF COMORBIDITY ON MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS 1980-2015: A LONGITUDINAL POPULATION-BASED STUDY IN WESTERN AUSTRALIA. Annals of the Rheumatic Diseases, 2021, 80, 55-56.	0.9	2
79	Comment on â€~No association of primary Sjögren's syndrome with Fcγ receptor gene variants'. Genes a Immunity, 2013, 14, 530-531.	nd 4.1	1
80	Recurrent podocytopathy in a patient with systemic lupus erythematosus. SAGE Open Medical Case Reports, 2017, 5, 2050313X1769599.	0.3	1
81	FRIO426â€No demonstrable effect of IL-23 receptor variants on clinical measures and IL23/ IL-17 levels in ankylosing spondylitis. , 2017, , .		1
82	Soluble erythropoietin receptor levels associate with inflammatory mediators but not with disease activity or cumulative organ damage in patients with systemic lupus erythematosus. European Journal of Inflammation, 2018, 16, 205873921881103.	0.5	1
83	Adult-onset Still's disease., 2011,, 849-858.e1.		1
84	Nonâ€gonococcal septic arthritis of native joints in Western Australia. A longitudinal populationâ€based study of frequency, risk factors and outcome. International Journal of Rheumatic Diseases, 2021, 24, 1386-1393.	1.9	1
85	SAT0576â€THE PREVALENCE OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW OF POPULATION-BASED STUDIES Annals of the Rheumatic Diseases, 2020, 79, 1246.2-1247.	0.9	1
86	FRIO192â€MORTALITY IN IGA VASCULITIS: A LONGITUDINAL POPULATION-BASED STUDY. Annals of the Rheumatic Diseases, 2020, 79, 679-679.	0.9	1
87	Temporal trends in hospitalisation for opportunistic infections in lupus patients in Western Australia. Lupus, 2022, 31, 1434-1440.	1.6	1
88	AB0171â€Thrombopoietin in Sle: Correlations with Clinical and Laboratory Parameters. A Cross-Sectional Study. Annals of the Rheumatic Diseases, 2014, 73, 859.3-859.	0.9	0
89	THU0001â€ERAP-1 Haplotype Influences Clinical Phenotype but not Cytokine Expression in Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 193.1-193.	0.9	0
90	A Remarkably Useless New Name in Rheumatology. Arthritis and Rheumatology, 2015, 67, 1685-1685.	5.6	0

#	Article	IF	CITATIONS
91	OP0018â€Hyperuricemia Increases Mortality Only in Patients with Gout and Existing Cardiovascular Disease. A Prospective Analysis from The Busselton Health Study. Annals of the Rheumatic Diseases, 2016, 75, 59.3-60.	0.9	0
92	Hoffa-Synovitis and Pain Sensitization: Comment on the Article by Neogi et al. Arthritis and Rheumatology, 2016, 68, 1791-1791.	5.6	0
93	419â€Hospitalisation for systemic lupus erythematosus in western australia doubles the all-cause mortality risk compared to controls, especially for medicare reliant and male patients. , 2017, , .		0
94	THU0688â€Disease flares, damage accrual and survival in anca-associated vasculitis. , 2017, , .		0
95	413â€Lupus nephritis in indigenous australians: incidence, histology and outcome. , 2017, , .		0
96	418â€Principal component analysis as a method to unravel the relation between disease activity and cytokine profiling in systemic lupus erythematosus. , 2017, , .		0
97	POS0297â€HOSPITAL ADMISSIONS FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN WESTERN AUSTRALIA HOSPITALS HAVE DECLINED OVER TIME. Annals of the Rheumatic Diseases, 2021, 80, 373.2-374.	0.9	0
98	POSO632â€THE LONGITUDINAL ASSOCIATIONS OF METHOTREXATE AND BIOLOGIC USE ON HOSPITAL ADMISSION FOR RHEUMATOID ARTHRITIS PATIENTS IN WESTERN AUSTRALIA POPULATION (1995- 2014). Annals of the Rheumatic Diseases, 2021, 80, 554.1-554.	0.9	0
99	AB0393â€PRE-EXISTING MORBIDITY AS A RISK FACTORS FOR MORTALITY IN IgA VASCULITIS. Annals of the Rheumatic Diseases, 2021, 80, 1224.3-1225.	0.9	O
100	ABO103â€THE ACCURACY OF ADMINISTRATIVE HEALTH DATA FOR IDENTIFYING PATIENTS WITH RHEUMATOID ARTHRITIS: A VALIDATION STUDY USING MEDICAL RECORDS IN WESTERN AUSTRALIA. Annals of the Rheumatic Diseases, 2021, 80, 1079.3-1080.	0.9	0
101	POS1147â€COSTS AND FACTORS AFFECTING HEALTH SERVICE UTILISATION IN PATIENTS WITH GOUT: A LONGITUDINAL, POPULATION-LEVEL LINKED DATA STUDY IN WESTERN AUSTRALIA. Annals of the Rheumatic Diseases, 2021, 80, 852.2-853.	0.9	0
102	POS0084â€SEPTIC ARTHRITIS IN CHILDREN. A LONGITUDINAL POPULATION-BASED STUDY IN WESTERN AUSTRALIA. Annals of the Rheumatic Diseases, 2021, 80, 250.2-250.	0.9	0
103	Incomplete Lupus Erythematosus. , 2007, , 473-481.		0
104	Incomplete Lupus Erythematosus. , 2011, , 707-717.		0
105	AB0693â€Gender as A Determinant of Functional Status and Disease Activity Measures in Patients with Longstanding Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2016, 75, 1141.3-1141.	0.9	0
106	THU0227â€Spinal fracture risk in ankylosing spondylitisin western australia., 2018,,.		0
107	OP0239 Pregnancy outcomes in patients with iga vasculitis. , 2018, , .		O
108	AB0586â€Current impact of ethnicity on renal histology and outcome of lupus nephritis. , 2018, , .		0

#	Article	IF	CITATIONS
109	AB1316â€Hospital admission trends and short-term outcome for iga vasculitis in children and adults in western australia. , 2018, , .		O
110	AB0158â $\in$ Histological and serological characteristics contribute to divergent outcomes for indigenous patients with lupus nephritis. , 2018, , .		0
111	Cancer in <scp>Antiâ€Neutrophil</scp> Cytoplasm <scp>Antibodyâ€Associated</scp> Vasculitis and Polyarteritis Nodosa in Australia: A <scp>Populationâ€Based</scp> Study. ACR Open Rheumatology, 2022, 4, 223-230.	2.1	0